Evotec SE (EVT.DE)
EUR 8.5
(-4.23%)
EUR 8.5
(-4.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.82 Million EUR | -107.61% |
| 2022 | -86.08 Million EUR | -0.82% |
| 2021 | 298.41 Million EUR | -4.1% |
| 2020 | 75.49 Million EUR | -18.63% |
| 2019 | 86.76 Million EUR | 28.36% |
| 2018 | 105.88 Million EUR | 62.42% |
| 2017 | 35.49 Million EUR | 18.76% |
| 2016 | 45.57 Million EUR | 381.46% |
| 2015 | 24.92 Million EUR | -8.77% |
| 2014 | 4.99 Million EUR | -17.82% |
| 2013 | -14.06 Million EUR | 36.87% |
| 2012 | 4.5 Million EUR | -30.35% |
| 2011 | 13.89 Million EUR | 54.18% |
| 2010 | 9.48 Million EUR | 154.2% |
| 2009 | -39.6 Million EUR | 65.5% |
| 2008 | -70 Million EUR | -37.29% |
| 2007 | -36.07 Million EUR | -82.9% |
| 2006 | -22.15 Million EUR | -3187.67% |
| 2005 | -18.43 Million EUR | 97.87% |
| 2004 | -67.55 Million EUR | 9.64% |
| 2003 | -31.12 Million EUR | -30.15% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -32.86 Million EUR | -546.93% |
| 2024 Q1 | -15.94 Million EUR | -36.3% |
| 2023 Q2 | -25.96 Million EUR | -2029.78% |
| 2023 Q4 | -22.88 Million EUR | -134.7% |
| 2023 Q1 | -1.21 Million EUR | -103.42% |
| 2023 Q3 | -9.75 Million EUR | 62.44% |
| 2023 FY | - EUR | -107.61% |
| 2022 FY | - EUR | -0.82% |
| 2022 Q1 | 60.31 Million EUR | -76.61% |
| 2022 Q2 | -6.5 Million EUR | -110.78% |
| 2022 Q3 | -14.16 Million EUR | -117.89% |
| 2022 Q4 | 35.65 Million EUR | 351.68% |
| 2021 FY | - EUR | -4.1% |
| 2021 Q3 | -114.53 Million EUR | -71.23% |
| 2021 Q4 | 257.85 Million EUR | 325.13% |
| 2021 Q2 | -66.89 Million EUR | -229.19% |
| 2021 Q1 | 51.77 Million EUR | 978.48% |
| 2020 Q2 | 240 Thousand EUR | -98.6% |
| 2020 FY | - EUR | -18.63% |
| 2020 Q4 | 4.8 Million EUR | -74.74% |
| 2020 Q1 | 17.17 Million EUR | -7.71% |
| 2020 Q3 | 19 Million EUR | 7820.0% |
| 2019 Q2 | 14.88 Million EUR | -17.24% |
| 2019 FY | - EUR | 28.36% |
| 2019 Q1 | 17.99 Million EUR | 932.13% |
| 2019 Q3 | 21.36 Million EUR | 43.48% |
| 2019 Q4 | 18.6 Million EUR | -12.9% |
| 2018 Q1 | 5.98 Million EUR | -44.16% |
| 2018 Q3 | 36.92 Million EUR | 97.38% |
| 2018 Q2 | 18.7 Million EUR | 212.86% |
| 2018 FY | - EUR | 62.42% |
| 2018 Q4 | 1.74 Million EUR | -95.28% |
| 2017 Q4 | 10.71 Million EUR | 28.31% |
| 2017 Q1 | 9.94 Million EUR | -35.0% |
| 2017 Q2 | 8.58 Million EUR | -13.76% |
| 2017 Q3 | 8.34 Million EUR | -2.72% |
| 2017 FY | - EUR | 18.76% |
| 2016 Q3 | 12 Million EUR | 114.51% |
| 2016 Q2 | 5.59 Million EUR | 29.04% |
| 2016 Q1 | 4.33 Million EUR | 130.88% |
| 2016 Q4 | 15.3 Million EUR | 27.54% |
| 2016 FY | - EUR | 381.46% |
| 2015 Q4 | -14.04 Million EUR | -4942.07% |
| 2015 Q3 | 290 Thousand EUR | -98.32% |
| 2015 Q2 | 17.26 Million EUR | 817.71% |
| 2015 Q1 | -2.4 Million EUR | -179.77% |
| 2015 FY | - EUR | -8.77% |
| 2014 FY | - EUR | -17.82% |
| 2014 Q2 | 418 Thousand EUR | 116.25% |
| 2014 Q4 | 3.01 Million EUR | -29.02% |
| 2014 Q3 | 4.24 Million EUR | 916.51% |
| 2014 Q1 | -2.57 Million EUR | -132.92% |
| 2013 Q1 | -1.72 Million EUR | -12.51% |
| 2013 FY | - EUR | 36.87% |
| 2013 Q4 | 7.81 Million EUR | 220.16% |
| 2013 Q3 | 2.44 Million EUR | 385.05% |
| 2013 Q2 | -856 Thousand EUR | 50.43% |
| 2012 Q4 | -1.53 Million EUR | -179.57% |
| 2012 Q2 | 4.05 Million EUR | 527.4% |
| 2012 Q3 | 1.92 Million EUR | -52.44% |
| 2012 FY | - EUR | -30.35% |
| 2012 Q1 | -949 Thousand EUR | 32.6% |
| 2011 Q2 | 2.24 Million EUR | 437.8% |
| 2011 Q1 | 418 Thousand EUR | -87.87% |
| 2011 FY | - EUR | 54.18% |
| 2011 Q4 | -1.4 Million EUR | -117.35% |
| 2011 Q3 | 8.11 Million EUR | 261.03% |
| 2010 Q4 | 3.44 Million EUR | 250.56% |
| 2010 Q1 | -1.13 Million EUR | -126.19% |
| 2010 Q2 | 1.12 Million EUR | 199.73% |
| 2010 Q3 | 983 Thousand EUR | -12.78% |
| 2010 FY | - EUR | 154.2% |
| 2009 FY | - EUR | 65.5% |
| 2009 Q1 | -13.68 Million EUR | 39.19% |
| 2009 Q2 | -5.71 Million EUR | 58.26% |
| 2009 Q3 | -3.14 Million EUR | 44.94% |
| 2009 Q4 | 4.31 Million EUR | 237.17% |
| 2008 Q3 | -7.13 Million EUR | 36.04% |
| 2008 Q4 | -22.5 Million EUR | -215.49% |
| 2008 Q2 | -11.15 Million EUR | 16.38% |
| 2008 Q1 | -13.33 Million EUR | -401.27% |
| 2008 FY | - EUR | -37.29% |
| 2007 Q1 | - EUR | 100.0% |
| 2007 FY | - EUR | -82.9% |
| 2007 Q2 | -6.67 Million EUR | 0.0% |
| 2007 Q4 | 4.42 Million EUR | 140.0% |
| 2007 Q3 | -11.06 Million EUR | -65.72% |
| 2006 FY | - EUR | -3187.67% |
| 2006 Q3 | -5.42 Million EUR | -29.39% |
| 2006 Q4 | -1.84 Million EUR | 65.97% |
| 2006 Q1 | -5.52 Million EUR | -20.11% |
| 2006 Q2 | -4.19 Million EUR | 24.11% |
| 2005 Q3 | - EUR | 100.0% |
| 2005 Q4 | -4.6 Million EUR | 0.0% |
| 2005 Q1 | -7.12 Million EUR | -33.72% |
| 2005 Q2 | -7.6 Million EUR | -6.69% |
| 2005 FY | - EUR | 97.87% |
| 2004 FY | - EUR | 9.64% |
| 2004 Q3 | - EUR | 100.0% |
| 2004 Q1 | -6.46 Million EUR | -1.54% |
| 2004 Q2 | -7.54 Million EUR | -16.84% |
| 2004 Q4 | -5.32 Million EUR | 0.0% |
| 2003 Q4 | - EUR | -18.91% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | - EUR | -30.15% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | - EUR | 0.0% |
| 2002 FY | - EUR | -87.72% |
| 2001 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| MPH Health Care AG | 33.31 Million EUR | 76.517% |
| Apontis Pharma AG | -12.94 Million EUR | 160.45% |
| Dermapharm Holding SE | 277.29 Million EUR | 97.179% |
| MERCK Kommanditgesellschaft auf Aktien | 5.52 Billion EUR | 99.858% |
| PharmaSGP Holding SE | 35.86 Million EUR | 78.189% |
| SynBiotic SE | -7.12 Million EUR | 209.834% |